ResearchMoz

Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape

GBI Research
Published Date » 2014-01-31
No. Of Pages » 120
   
 GBI Research, has released the pharma report – “Hepatitis C Therapeutics in Major Developed Markets to 2019 – Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape”. The current Hepatitis C treatment landscape consists of a combination of pegylated interferon, ribavirin and, in patients infected with genotype 1 hepatitis C, one of two direct-acting antiviral agents (DAAs). Products with these mechanisms of action have performed strongly in the commercial setting, with the market leader Incivek (a DAA) having reached blockbuster sales. However, these products are very poorly tolerated and only moderately efficacious. The approval of the DAA Sovaldi in December 2013 changed this, with a complete viral clearance...
Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Signs and Symptoms
2.2 Etiology and Risk Factors
2.3 Pathophysiology
2.4 Epidemiology
2.4.1 US and Canada
2.4.2 Europe
2.4.3 Japan
2.4.4 Regional Prevalence of Hepatitis C Genotypes
2.5 Prognosis
2.6 Diagnosis and Screening
2.7 Treatment
2.8 Treatment Algorithms

3 Marketed Products
3.1 Ribavirin
3.2 Pegasys (Peginterferon alfa 2a) and PegIntron (Peginterferon alfa 2b) – Hoffmann La Roche and Merck & Co
3.2.1 Pegasys – Hoffmann La Roche
3.2.2 PegIntron – Merck & Co
3.3 Incivek (telaprevir) – Vertex Pharmaceuticals and Janssen-Cilag
3.4 Victrelis (boceprevir) – Merck & Co
3.5 Olysio (simeprevir) – Johnson and Johnson
3.6 Sovaldi (sofosbuvir) – Gilead Sciences
3.7 Heat Map for Marketed Products

4 Developmental Pipeline
4.1 Overall Pipeline
4.2 Mechanisms of Action
4.3 Clinical Trials
4.3.1 Clinical Trial Failure Rates
4.3.2 Clinical Trial Enrollment
4.3.3 Clinical Trial Duration
4.3.4 Clinical Trial Design
4.4 Promising Pipeline Drugs
4.4.1 Sovaldi plus Ledipasvir – Gilead Sciences
4.4.2 Daclatasvir – Bristol-Myers Squibb
4.4.3 Faldaprevir – Boehringer-Ingelheim
4.4.4 Peginterferon lambda 1a – Bristol-Myers Squibb
4.4.5 ABT-450 – AbbVie and Enanta
4.4.6 Vaniprevir – Merck & Co
4.5 Heat Map and Competitor Matrix for Pipeline Products
4.6 Conclusion

5 Market Forecast to 2019
5.1 Global Market
5.1.1 Treatment Usage Patterns
5.1.2 Market Size
5.2 US
5.2.1 Treatment Usage Patterns
5.2.2 Market Size
5.3 Canada
5.3.1 Treatment Usage Patterns
5.3.2 Market Size
5.4 Top Five European Markets
5.4.1 Treatment Usage Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Usage Patterns
5.5.2 Market Size

6 Drivers and Barriers
6.1 Drivers
6.1.1 Approval of Sovaldi and Olysio in 2013
6.1.2 Large and Exceptionally Promising Late-Stage Pipeline
6.1.3 Favorable Pricing Structure in the US
6.1.4 Weak Exposure to Generics and Biosimilars during the Forecast Period
6.1.5 Increasing Volume of Treated Patients
6.1.6 Rapid Incorporation of Novel Products into Treatment Guidelines
6.2 Barriers
6.2.1 Low Rates of Diagnosis and Treatment in Certain Markets
6.2.2 Unfavorable Pricing Structures in the EU and Japan
6.2.3 Rapidly Increasing Competition in the Market

7 Licensing and Co-development deals
7.1 Licensing Deals
7.1.1 Vertex Pharma Enters into Licensing Agreement with Alios BioPharma for ALS-2200 and ALS-2158
7.1.2 Bristol-Myers Squibb Company Enters into Licensing Agreement with ZymoGenetics
7.1.3 Human Genome Sciences Enters Into Licensing Agreement With Novartis
7.1.4 Roche Signs Licensing Agreement With InterMune
7.1.5 Idenix Enters Into A Licensing Agreement With Novartis Pharma
7.1.6 Enanta Pharma Enters into Licensing Agreement with Novartis for Hepatitis C Program
7.1.7 Medivir Enters into Licensing Agreement with Tibotec
7.1.8 Metabasis Therapeutics Enters Into Collaboration And Licensing Agreement With Roche
7.1.9 Schering-Plough And PTC Therapeutics Enter Into A Collaboration And Licensing Agreement
7.1.10 Presidio Pharma Enters into Licensing Agreement with XTL BioPharma
7.2 Co-development Deals
7.2.1 Vertex Pharma Enters into Co-Development Agreement with Janssen Pharmaceutica
7.2.2 Abbott Labs Enters into Agreement with Enanta Pharma
7.2.3 Genelabs Enters into Collaboration with Novartis
7.2.4 Regulus Therapeutics Enters into an Agreement with GlaxoSmithKline
7.2.5 Tacere Therapeutics Enters into Agreement with Pfizer
7.2.6 Biota Holdings Enters into an Agreement with Boehringer Ingelheim

8 Appendix
8.1 Sources
8.2 Sources for Heat Maps
8.3 All Pipeline Products, by Stage of Development
8.3.1 Discovery
8.3.2 Preclinical and IND/CTA-filed
8.3.3 Phase I
8.3.4 Phase II
8.3.5 Phase III and Pre-registration
8.3.6 Undisclosed
8.4 Tabular Forecast Data
8.4.1 Global
8.4.2 US
8.4.3 Canada
8.4.4 UK
8.4.5 France
8.4.6 Germany
8.4.7 Italy
8.4.8 Spain
8.4.9 Japan
8.5 Market Definition
8.6 Abbreviations
8.7 Methodology
8.7.1 Coverage
8.7.2 Secondary Research
8.7.3 Primary Research
8.7.4 Therapeutic Landscape
8.7.5 Epidemiology-Based Forecasting
8.7.6 Market Size by Geography
8.7.7 Geographical Landscape
8.7.8 Pipeline Analysis
8.8 Contact Us
8.9 Disclaimer

List of Tables

Table 1: Hepatitis C, Top Five European Countries, Disease Prevalence (%), 2011
Table 2: Hepatitis C, Top Five European Markets, Most Common Risk Factors for Infection (%), 2011
Table 3: Hepatitis C, Global, Estimated Distribution of Hepatitis C Genotypes (%), 2013
Table 4: Market for Hepatitis C, Sources for Heat Maps
Table 5: Hepatitis C Therapeutics, Global, All Pipeline Products (Discovery), 2013
Table 6: Hepatitis C Therapeutics, Global, All Pipeline Products (Preclinical and IND/CTA-filed), 2013
Table 7: Hepatitis C, Global, All Pipeline Products (Phase I), 2013
Table 8: Hepatitis C Therapeutics, Global, All Pipeline Products (Phase II), 2013
Table 9: Hepatitis C Therapeutics, Global, All Pipeline Products (Phase III), 2013
Table 10: Hepatitis C Therapeutics, Global, All Pipeline Products (Undisclosed), 2013
Table 11: Market for Hepatitis C, Global, Forecast Data, 2012–2019
Table 12: Market for Hepatitis C, US, Forecast Data, 2012–2019
Table 13: Market for Hepatitis C, Canada, Forecast Data, 2012–2019
Table 14: Market for Hepatitis C, UK, Forecast Data, 2012–2019
Table 15: Market for Hepatitis C, France, Forecast Data, 2012–2019
Table 16: Market for Hepatitis C, Germany, Forecast Data, 2012–2019
Table 17: Market for Hepatitis C, Italy, Forecast Data, 2012–2019
Table 18: Market for Hepatitis C, Spain, Forecast Data, 2012–2019
Table 19: Market for Hepatitis C, Japan, Forecast Data, 2012–2019

List of Figures

Figure 1: Market for Hepatitis C, Global, Treatment Algorithm (Genotype 1, Triple Therapy with Incivek), 2013
Figure 2: Market for Hepatitis C, Global, Treatment Algorithm (Genotype 1, Triple Therapy with Victrelis), 2013
Figure 3: Market for Hepatitis C, Global, Treatment Algorithm (Genotypes 2 to 7), 2013
Figure 4: Market for Hepatitis C, Global, Sales of Pegasys and PegIntron ($m), 2002–2012
Figure 5: Market for Hepatitis C, Global, Heat Map for Marketed Products, 2013
Figure 6: Market for Hepatitis C, Global, Developmental Pipeline, 2013
Figure 7: Market for Hepatitis C, Global, Pipeline by Mechanism of Action and Molecule Type, 2013
Figure 8: Market for Hepatitis C, Global, Clinical Trial Failure Rate by Molecule Type, 2006–2013
Figure 9: Market for Hepatitis C, Global, Clinical Trial Failure Rates by Mechanism of Action, 2006–2013
Figure 10: Market for Hepatitis C, Global, Clinical Trial Enrollment by Molecule Type, 2006–2013
Figure 11: Market for Hepatitis C, Global, Clinical Trial Enrollment by Mechanism of Action, 2006–2013
Figure 12: Market for Hepatitis C, Clinical Trial Duration by Molecule Type, 2006–2013
Figure 13: Market for Hepatitis C, Global, Clinical Trial Duration by Mechanism of Action, 2006–2013
Figure 14: Market for Hepatitis C, Global, Frequency of Clinical Trial Primary Endpoints Per Clinical Trial, 2006–2013
Figure 15: Market for Hepatitis C, Global, Frequency of Clinical Trial Endpoints Primary within Clinical Development Programs, 2006–2013
Figure 16: Market for Hepatitis C, Global, Usage of HCV Genotypes as Clinical Trial Inclusion Criteria, 2006–2013
Figure 17: Market for Hepatitis C, Global, Sales Forecast for Sovaldi plus ledipasvir ($m), 2015–2019
Figure 18: Market for Hepatitis C, Global, Sales Forecast for daclatasvir (monotherapy) ($m), 2015–2019
Figure 19: Market for Hepatitis C, Global, Sales Forecast for daclatasvir plus asunaprevir plus BMS-791325 ($m), 2015–2019
Figure 20: Market for Hepatitis C, Global, Sales Forecast for faldaprevir ($m), 2015–2019
Figure 21: Market for Hepatitis C, Global, Sales Forecast for peginterferon lambda 1a ($m), 2015–2019
Figure 22: Market for Hepatitis C, Global, Sales Forecast for ABT-450 ($m), 2015–2019
Figure 23: Market for Hepatitis C, Global, Sales Forecast for ABT-450 plus ABT-333 plus ABT-267 ($m), 2015–2019
Figure 24: Market for Hepatitis C, Global, Sales Forecast for vaniprevir, 2015–2019
Figure 25: Market for Hepatitis C, Global, Heat Map for Pipeline Products, 2013
Figure 26: Market for Hepatitis C, Global, Competitor Matrix, 2013
Figure 27: Market for Hepatitis C, Global, Market Growth and Size, 2012–2019
Figure 28: Market for Hepatitis C, Global, Treatment Patterns, 2012–2019
Figure 29: Market for Hepatitis C, Global, Market Size ($bn), 2012–2019
Figure 30: Market for Hepatitis C, US, Treatment Usage Patterns, 2012–2019
Figure 31: Market for Hepatitis C, US, Market Size ($bn), 2012–2019
Figure 32: Market for Hepatitis C, Canada, Treatment Usage Patterns, 2012–2019
Figure 33: Market for Hepatitis C, Canada, Market Size ($m), 2012–2019
Figure 34: Market for Hepatitis C, Top Five European Markets, Treatment Patterns, 2012–2019
Figure 35: Market for Hepatitis C, Top Five European Markets, Annual Cost of Therapy ($), 2012–2019
Figure 36: Market for Hepatitis C, Top Five European Markets, Market Size ($m), 2012–2019
Figure 37: Market for Hepatitis C, Japan, Treatment Usage Patterns, 2012–2019
Figure 38: Market for Hepatitis C, Japan, Market Size ($m), 2012–2019
Figure 39: Market for Hepatitis C, Global, Network of Licensing Deals, 2006–2013
Figure 40: Market for Hepatitis C, Global, Licensing Deals by Year, 2006–2013
Figure 41: Market for Hepatitis C, Global, Licensing Deals, 2006–2013
Figure 42: Market for Hepatitis C, Global, Network of Co-Development Deals, 2006–2013
Figure 43: Market for Hepatitis C, Global, Co-Development Deals by Year, 2006–2013
Figure 44: GBI Research Market Forecasting Model

Upcoming Reports:

Disposable Syringes Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018
By - Transparency Market Research
Disposable syringes are widely used by physicians and patients at home in diagnosis and monitoring diseased conditions, along with administering medicines. Disposable syringes offer advantages over non-disposable with respect to cost, safety, ease of use and hygiene. The product segments of the global disposable syringes market include auto-disable syringes, auto-retractable safety syringes, single use syringes, insulin syringes and pen injectors, advanced injection devices, needle-free injectors, and others such as pre-filled syringes, blood collection needles and vaccination...
Aesthetic Lasers And Energy Devices Market: Global Industry Analysis, Market Size, Share, Trends, Analysis, Growth, And Forecast, 2012 - 2018
By - Transparency Market Research
Description Aesthetic laser and energy devices market focuses on the physiology of aging and wrinkled skin and uses technical based procedures for rectification of these processes. Physicians working on aesthetic science are skilled in both non-invasive and invasive procedures, and typically utilize a combination of both to meet the needs of the patients. The major driving factors of the aesthetic lasers and energy devices market are the increase in the prevalence of obesity, along with patients preferring hospital care to home care, because the former provides fast and...
Rheumatoid Arthritis Pharmacotherapeutics Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018
By - Transparency Market Research
Treatment options for rheumatoid arthritis (RA) are expanding as a result of increasing research activities and more explicit understanding of the pathophysiology of diseases. For the treatment of RA, novel selective inhibitors such as cyclooxygenase-2 (COX-2) are used along with the non-steroidal anti-inflammatory drugs. Although COX-2 is used in treatment of RA, it has several side effects associated with the upper gastrointestinal region.  Currently, use of disease modifying antirheumatic drugs is recommended by most professionals in the early stages of disease. ...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

LG, Samsung to showcase home tech at IFA
Sep 2, 2014  
With this year’s IFA tech fair just round the corner, the participating companies are gearing up to showcase their latest gadgets. LG Electronics will be putting up an all-new set of appliances on display at the Internationale Funkausstellung (IFA) to be held from September 5 at Berlin. Televisions and wireless vacuum cleaners are two of its top devices on exhibit. LG’s...
Wine Consumption Prevents Cardiovascular Disease Only Among those who Exercise: Study
Sep 2, 2014  
Results from a latest study indicate that wine only prevents cardiovascular disease in people who engage in regular physical exercise. The study – In Vino Veritas – was presented by Prof. Milos Taborsky at the ESC Congress.  Prof. Taborsky, from the Czech Republic, said that this was the initial randomized trial that weighs both red and white wine against markers of...
New Drug Shows Early Promise against Heart Attacks and Strokes
Sep 1, 2014  
Sanofi and Regeneron Pharmaceuticals have been working on a new experimental drug that aims to lower cholesterol. Early tests have shown that the drug cuts down risks of heart attacks and strokes in clinical trials by half. The test report says that the results are not conclusive as the analysis was performed retrospectively. The study does provide the positive result that...
New Materials Creation Strategy
Sep 1, 2014  
Scientists always aim at theorizing about new compounds and materials; however after Researchers have made use of X-ray scattering in a process known as molecular beam epitaxy (MBE) to understand atom behavior as a kind of material called as layered oxides were getting formed. For computational predictions of new materials, the available observations were utilized for providing insights on...
Western Africa economies hit by Ebola travel ban
Aug 28, 2014  
With over 1,400 people dead due to the fatal Ebola outbreak in African countries, travel services have either banned or limited operations to the western region, severely hitting economies of the area. Budgetary resources are being utilized rapidly and economic growth has dropped by 4% as international projects and trips have been cancelled. Transport companies have cut off the region...